Esophagectomy versus definitive chemoradiotherapy for patients with clinical stage N0 and pathological stage T1b esophageal squamous cell carcinoma after endoscopic submucosal dissection: study protocol for a multicenter randomized controlled trial (Ad-ESD Trial)

Yang Yang, Yuchen Su, Xiaobin Zhang, Jun Liu, Hong Zhang, Bin Li, Rong Hua, Lijie Tan, Hezhong Chen, Zhigang Li, Yang Yang, Yuchen Su, Xiaobin Zhang, Jun Liu, Hong Zhang, Bin Li, Rong Hua, Lijie Tan, Hezhong Chen, Zhigang Li

Abstract

Background: Esophagectomy is still advised as an additional treatment for pathological T1b (pT1b) esophageal squamous cell carcinoma (ESCC) following attempted endoscopic resection (ER). ER followed with definitive chemoradiotherapy (dCRT) has shown increased quality of life as well as comparable oncological outcomes to esophagectomy. However, there is no well-designed phase III trial to compare the two treatments for patients with pT1b ESCC.

Methods: One hundred seventy-six patients with clinical stage N0 (cN0) and pT1b ESCC will be recruited at three centers and randomly assigned to the esophagectomy group or the dCRT group. The clinical lymph node status will be measured by image examination, including computer tomography and positron emission tomography-computed tomography. The pathological tumor status will be diagnosed after endoscopic submucosal dissection (ESD). All patients will be followed up for 60 months after randomization. The primary endpoint is 5-year overall survival. The secondary endpoints are quality of life, related adverse events, 3-year overall survival, and relapse-free survival rates.

Discussion: To the best of our knowledge, this is the first phase III randomized controlled trial to compare esophagectomy and dCRT for patients with cN0-pT1b ESCC after ESD. Based on the results of this study, we will show whether dCRT will benefit patients more than esophagectomy, which will contribute more high-quality evidence to the primary salvage treatment for these patients.

Trial registration: ClinicalTrials.gov, NCT04135664 . Registered on Aug. 10, 2019.

Keywords: Definitive chemoradiotherapy; Endoscopic submucosal dissection; Esophageal cancer; Esophagectomy; Randomized controlled trial; Submucosal lesion.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Flow chart of the trial

References

    1. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–1953. doi: 10.1002/ijc.31937.
    1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi: 10.3322/caac.21338.
    1. Rice TW, Patil DT, Blackstone EH. 8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. Ann Cardiothorac Surg. 2017;6(2):119–130. doi: 10.21037/acs.2017.03.14.
    1. Kato H, Tachimori Y, Mizobuchi S, Igaki H, Ochiai A. Cervical, mediastinal, and abdominal lymph node dissection (three-field dissection) for superficial carcinoma of the thoracic esophagus. Cancer. 1993;72(10):2879–2882. doi: 10.1002/1097-0142(19931115)72:10<2879::AID-CNCR2820721004>;2-Q.
    1. Gertler R, Stein HJ, Langer R, Nettelmann M, Schuster T, Hoefler H, et al. Long-term outcome of 2920 patients with cancers of the esophagus and esophagogastric junction: evaluation of the New Union Internationale Contre le Cancer/American Joint Cancer Committee staging system. Ann Surg. 2011;253(4):689–698. doi: 10.1097/SLA.0b013e31821111b5.
    1. Akutsu Y, Uesato M, Shuto K, Kono T, Hoshino I, Horibe D, et al. The overall prevalence of metastasis in T1 esophageal squamous cell carcinoma: a retrospective analysis of 295 patients. Ann Surg. 2013;257(6):1032–1038. doi: 10.1097/SLA.0b013e31827017fc.
    1. Endo M, Yoshino K, Kawano T, Nagai K, Inoue H. Clinicopathologic analysis of lymph node metastasis in surgically resected superficial cancer of the thoracic esophagus. Dis Esophagus. 2000;13(2):125–129. doi: 10.1046/j.1442-2050.2000.00100.x.
    1. Dubecz A, Kern M, Solymosi N, Schweigert M, Stein HJ. Predictors of Lymph Node Metastasis in Surgically Resected T1 Esophageal Cancer. Ann Thorac Surg. 2015;99(6):1879–1885. doi: 10.1016/j.athoracsur.2015.02.112.
    1. Nemoto K, Yamada S, Nishio M, Aoki M, Nakamura R, Matsumoto Y, et al. Results of radiation therapy for superficial esophageal cancer using the standard radiotherapy method recommended by the Japanese Society of Therapeutic Radiology and Oncology (JASTRO) Study Group. Anticancer Res. 2006;26(2B):1507–1512.
    1. Motoori M, Yano M, Ishihara R, Yamamoto S, Kawaguchi Y, Tanaka K, et al. Comparison between radical esophagectomy and definitive chemoradiotherapy in patients with clinical T1bN0M0 esophageal cancer. Ann Surg Oncol. 2012;19(7):2135–2141. doi: 10.1245/s10434-012-2231-8.
    1. Wang J, Zhu X-N, Zhu L-L, Chen W, Ma Y-H, Gan T, et al. Efficacy and safety of endoscopic submucosal tunnel dissection for superficial esophageal squamous cell carcinoma and precancerous lesions. World J Gastroenterol. 2018;24(26):2878–2885. doi: 10.3748/wjg.v24.i26.2878.
    1. Suzuki G, Yamazaki H, Aibe N, Masui K, Sasaki N, Shimizu D, et al. Endoscopic submucosal dissection followed by chemoradiotherapy for superficial esophageal cancer: choice of new approach. Radiat Oncol. 2018;13(1):246. doi: 10.1186/s13014-018-1195-7.
    1. Kawaguchi G, Sasamoto R, Abe E, Ohta A, Sato H, Tanaka K, et al. The effectiveness of endoscopic submucosal dissection followed by chemoradiotherapy for superficial esophageal cancer. Radiat Oncol. 2015;10:31. doi: 10.1186/s13014-015-0337-4.
    1. Ikeda A, Hoshi N, Yoshizaki T, Fujishima Y, Ishida T, Morita Y, et al. Endoscopic Submucosal Dissection (ESD) with Additional Therapy for Superficial Esophageal Cancer with Submucosal Invasion. Intern Med. 2015;54(22):2803–2813. doi: 10.2169/internalmedicine.54.3591.
    1. Kurokawa Y, Muto M, Minashi K, Boku N, Fukuda H, Gastrointestinal Oncology Study Group of Japan Clinical Oncology Group (JCOG) A phase II trial of combined treatment of endoscopic mucosal resection and chemoradiotherapy for clinical stage I esophageal carcinoma: Japan Clinical Oncology Group Study JCOG0508. Jpn J Clin Oncol. 2009;39(10):686–689. doi: 10.1093/jjco/hyp078.
    1. Minashi K, Nihei K, Mizusawa J, Takizawa K, Yano T, Ezoe Y, et al. Efficacy of Endoscopic Resection and Selective Chemoradiotherapy for Stage I Esophageal Squamous Cell Carcinoma. Gastroenterology. 2019;157(2):382–390. doi: 10.1053/j.gastro.2019.04.017.
    1. Wang H, Shen Y, Feng M, Zhang Y, Jiang W, Xu S, et al. Outcomes, quality of life, and survival after esophagectomy for squamous cell carcinoma: A propensity score-matched comparison of operative approaches. J Thorac Cardiovasc Surg. 2015;149(4):1006–1014. doi: 10.1016/j.jtcvs.2014.12.063.
    1. van der Sluis PC, Ruurda JP, RJJ V, van der Horst S, Haverkamp L, Siersema PD, et al. Oncologic Long-Term Results of Robot-Assisted Minimally Invasive Thoraco-Laparoscopic Esophagectomy with Two-Field Lymphadenectomy for Esophageal Cancer. Ann Surg Oncol. 2015;22(Suppl 3):S1350–S1356. doi: 10.1245/s10434-015-4544-x.
    1. Biere SS, van Berge Henegouwen MI, Maas KW, Bonavina L, Rosman C, Garcia JR, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet. 2012;379(9829):1887–1892. doi: 10.1016/S0140-6736(12)60516-9.
    1. Ajani JA, D’Amico TA, Bentrem DJ, Chao J, Corvera C, Das P, et al. Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2019;17(7):855–883. doi: 10.6004/jnccn.2019.0033.
    1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–376. doi: 10.1093/jnci/85.5.365.
    1. Blazeby JM, Conroy T, Hammerlid E, Fayers P, Sezer O, Koller M, et al. Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer. Eur J Cancer. 2003;39(10):1384–1394. doi: 10.1016/S0959-8049(03)00270-3.
    1. Tachimori Y, Ozawa S, Numasaki H, Ishihara R, Matsubara H, Muro K, et al. Comprehensive Registry of Esophageal Cancer in Japan, 2011. Esophagus. 2018;15(3):127–152. doi: 10.1007/s10388-018-0614-z.
    1. Qin J, Peng Y, Chen W, Ma H, Zheng Y, Li Y, et al. Comparative study of esophagectomy, endoscopic therapy, and radiotherapy for cT1N0M0 esophageal cancer in elderly patients: A SEER database analysis. Thorac Cancer. 2019;10(7):1511–1520. doi: 10.1111/1759-7714.13080.
    1. Hisano O, Nonoshita T, Hirata H, Sasaki T, Watanabe H, Wakiyama H, et al. Additional radiotherapy following endoscopic submucosal dissection for T1a-MM/T1b-SM esophageal squamous cell carcinoma improves locoregional control. Radiat Oncol. 2018;13(1):14. doi: 10.1186/s13014-018-0960-y.
    1. Goense L, Meziani J, Borggreve AS, van Rossum PS, Meijer GJ, Ruurda JP, et al. Role of adjuvant chemoradiotherapy after endoscopic treatment of early-stage esophageal cancer: a systematic review. Minerva Chir. 2018;73(4):428–436.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren